BLA 125058 · Biomarin
Aldurazyme
Laronidase · Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Apr 30, 2003
Approved uses
3
Original approval plus efficacy supplements
Registered trials
18
4 Phase 3, 1 recruiting
FAERS reports
4,133
2,841 serious, 671 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, and ACUTE RESPIRATORY COMPLICATIONS ASSOCIATED WITH ADMINISTRATION WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, and ACUTE RESPIRATORY COMPLICATIONS ASSOCIATED WITH ADMINISTRATION See full prescribing information for complete boxed warning . Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, discontinue ALDURAZYME immediately and initiate appropriate medical treatment. ( 5.1 ) Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions and require additional monitoring. Appropriate respiratory support should be available during infusion. ( 5.2 ) Hypersensitivity Reactions...
What it is approved for
From the label in effect Sep 11, 2026.
ALDURAZYME ® is indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms. ALDURAZYME is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for the treatment of adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for the treatment of patients with the Scheie form of MPS I who have moderate to severe symptoms. ( 1 ) Limitations of Use: The risks and benefits of treating mildly affected patients with the Scheie form have not been established. ( 1 ) ALDURAZYME has not been evaluated for effects on the central nervous system manifestations of the disorder. ( 1 ) Limitations of Use The safety and effectiveness of treating mildly affected patients with the Scheie form have not been established. The effect of ALDURAZYME on central nervous system manifestations of the disorder has not been determined.
Mechanism: Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis I (MPS I) is characterized by the deficiency of α-L-iduronidase, a lysosomal hydrolase which catalyzes the hydrolysis of terminal α-L-iduronic acid residues of dermatan sulfate and heparan sulfate. Reduced or absent α-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction. The...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 20, 2009 Supplement 161 · Efficacy OrphanLetterLabel
- May 20, 2009 Supplement 160 · Efficacy OrphanLabelLetter
- Apr 30, 2003 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLetterLabel
1 products under this application
- ALDURAZYME · LARONIDASE 2.9MG/ML · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Laronidase" as an intervention, any sponsor and status, largest first.
- Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) IPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00912925 · 45 participants · Start Dec 2000 · Primary completion Sep 2001
Drug: rhIDU (recombinant human-Alpha-L-Iduronidase); Placebo · For: Mucopolysaccharidosis I; Hurlers Syndrome; Hurler-Scheie Syndrome
Sites: New York, New York; Chapel Hill, North Carolina; Vancouver, Canada · 4 sites in all
- Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) PatientsPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00146770 · 45 participants · Start May 2001 · Primary completion Mar 2005
Drug: Aldurazyme; Aldurazyme and 1 more · For: Mucopolysaccharidosis I; Hurler's Syndrome; Hurler-Scheie Syndrome and 1 more
Sites: Mobile, Alabama; Atlanta, Georgia; Rochester, New York · 25 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00144781 · 34 participants · Start Dec 2004 · Primary completion Jan 2006
Drug: Aldurazyme (Recombinant Human Alpha-L-Iduronidase); Aldurazyme (Recombinant Human Alpha-L-Iduronidase) and 2 more · For: Mucopolysaccharidosis I; Hurler's Syndrome; Hurler-Scheie Syndrome and 1 more
Sites: Florianópolis, Brazil; Belo Horizonte, Brazil; Porto Alegre, Brazil · 5 sites in all
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
NCT00638547 · 26 participants · Start Jan 2, 2008 · Primary completion Feb 18, 2017
Drug: IRT Laronidase · For: Hurler Syndrome
Sites: Minneapolis, Minnesota
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
NCT00176891 · 25 participants · Start Mar 2004 · Primary completion Nov 2012
Drug: Laronidase ERT · For: Mucopolysaccharidosis I; Hurler Syndrome
Sites: Minneapolis, Minnesota
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00144768 · 25 participants (planned) · Start Jul 2004 · Primary completion May 2007
Drug: laronidase · For: Mucopolysaccharidosis I; Hurler's Syndrome; Hurler-Scheie Syndrome and 1 more
Sites: Los Angles, California; Hartford, Connecticut; Milwaukee, Wisconsin
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00146757 · 20 participants · Start Oct 2002 · Primary completion May 2005
Drug: Aldurazyme (Recombinant Human Alpha-L-Iduronidase); Aldurazyme (Recombinant Human Alpha-L-Iduronidase) · For: Mucopolysaccharidosis I; Hurler Syndrome; Hurler-Scheie Syndrome and 1 more
Sites: Lyon, France; Kinderklinik, Germany; Rotterdam, Netherlands · 4 sites in all
- Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I PatientsPivotal-lookingCompleted
CinnagenIndustry
NCT06406153 · 12 participants · Start Sep 10, 2022 · Primary completion Aug 12, 2023
Drug: Laronidase; Antihistamine and 1 more · For: Mucopolysaccharidosis Type 1
Sites: Mashhad, Iran; Tehran, Iran · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia517
- pneumonia246
- vomiting207
- dyspnoea198
- malaise190
- cough187
- fatigue151
- death141
- headache133
- influenza131
- pain128
- condition aggravated127
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 81 |
| 2005 | 60 |
| 2006 | 28 |
| 2007 | 111 |
| 2008 | 61 |
| 2009 | 59 |
| 2010 | 51 |
| 2011 | 73 |
| 2012 | 90 |
| 2013 | 132 |
| 2014 | 133 |
| 2015 | 208 |
| 2016 | 249 |
| 2017 | 264 |
| 2018 | 325 |
| 2019 | 261 |
| 2020 | 259 |
| 2021 | 317 |
| 2022 | 353 |
| 2023 | 371 |
| 2024 | 257 |
| 2025 | 202 |
| 2026 | 188 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aldurazyme (Laronidase)
2024 spending
$7.4M
Beneficiaries
11
162 claims
Per beneficiary
$672,291
$214.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,500,167 |
| 2021 | $7,750,225 |
| 2022 | $8,107,409 |
| 2023 | $7,301,136 |
| 2024 | $7,395,200 |
Part B: Aldurazyme (Laronidase) · HCPCS J1931
2024 spending
$784K
Beneficiaries
n/a
64 claims
Per beneficiary
n/a
2024 ASP limit $38.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,253,058 |
| 2021 | $1,525,481 |
| 2022 | $903,985 |
| 2023 | $1,026,704 |
| 2024 | $784,277 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of laronidase in Chinese patients with mucopolysaccharidosis type I: a phase IV, single-arm, open-label, multicenter study.
Liang Y, Yang YL, Zou CC, et al. · Orphanet J Rare Dis 2025 · Multicenter Study, Clinical Trial, Phase IV
- Laronidase for treating mucopolysaccharidosis type I.
El Dib RP, Pastores GM · Genet Mol Res 2007 · Meta-Analysis, Systematic Review
- A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I.
Giugliani R, Rojas VM, Martins AM, et al. · Mol Genet Metab 2009 · Multicenter Study, Randomized Controlled Trial
- Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation.
Polgreen LE, Lund TC, Braunlin E, et al. · Pediatr Res 2020 · Clinical Trial, Research Support, N.I.H., Extramural
- Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience.
Pitz S, Ogun O, Bajbouj M, et al. · Arch Ophthalmol 2007 · Clinical Trial, Phase III, Multicenter Study
- Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes.
Lund TC, Miller WP, Liao AY, et al. · Sci Rep 2019 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: BioMarin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.